Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8608126 | 0.88 | LMNA (0.45) | GAAKMT2AHSD17B10LMNARECQL | |
| SCHEMBL5063742 | 0.83 | GAA (0.58) | GAAKMT2AHSD17B10HPGDMLYCD | |
| SCHEMBL11437810 | 0.83 | MAOB (0.53) | GAAKMT2ALMNARECQLMAOB | |
| SCHEMBL11632170 | 0.81 | PTGS1 (0.56) | GAAKMT2ALMNARECQLNPSR1 | |
| SCHEMBL2908793 | 0.80 | HSD17B10 (0.78) | GAAKMT2AHSD17B10HPGDMLYCD | |
| SCHEMBL18748508 | 0.80 | GAA (0.62) | GAAKMT2AHSD17B10HPGDMLYCD | |
| SCHEMBL8607170 | 0.80 | CYP1A2 (0.41) | GAAKMT2AHSD17B10LMNARECQL | |
| SCHEMBL20206991 | 0.80 | GAA (0.61) | GAAKMT2AHSD17B10HPGDMLYCD | |
| SCHEMBL16610341 | 0.79 | MLYCD (0.51) | GAAKMT2AHSD17B10HPGDMLYCD | |
| SCHEMBL5058222 | 0.79 | NR5A2 (0.65) | GAAKMT2AHSD17B10HPGDMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3387010-A1 | COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES | Intrexon Corporation (US) | 2018-10-17 | — | — | EP | claimed |
| WO-2017083750-A1 | COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES | INTREXON CORPORATION (US) | 2017-05-18 | — | — | WO | claimed |
| US-20060240088-A1 | Caged ligands and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-10-26 | — | — | US | claimed |
| US-7045315-B2 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2006-05-16 | — | — | US | claimed |
| WO-2004037983-A2 | CAGED LIGANDS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2004-05-06 | — | — | WO | claimed |
| US-6723531-B2 | DNA CONSTRUCT COMPRISING SAID EXOGENOUS GENE UNDER THE CONTROL OF AN ECDYSONE RESPONSE ELEMENT; AND A MODIFIED ECDYSONE RECEPTOR WHICH, IN THE PRESENCE OF A LIGAND THEREFOR, BINDS TO SAID ECDYSONE RESPONSE ELEMENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-04-20 | — | — | US | claimed |
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | THE SALK INSTITUTE OF BIOLOGICAL STUDIES | 2002-12-12 | — | — | US | claimed |
| US-20020177564-A1 | METHOD FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | HOWARD HUGHES MEDICAL INSTITUTE | 2002-11-28 | — | — | US | claimed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | claimed |
| US-20260098063-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | PRECIGEN INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4716690-A2 | NOVEL ADENOVIRUS VACCINE THERAPY FOR THE TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS | Precigen, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4716689-A2 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | Precigen, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260035432-A1 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | PRECIGEN, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250325665-A1 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | PRECIGEN, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20020119521-A1 | Novel ecdysone receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2002-08-29 | — | — | US | disclosed |
| WO-2002066613-A2 | NOVEL ECDYSONE RECEPTOR/INVERTEBRATE RETINOID X RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE HOLDINGS, INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066614-A2 | CHIMERIC RETINOID X RECEPTORS AND THEIR USE IN A NOVEL ECDYSONE RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE HOLDINGS, INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| US-20020110861-A1 | Multiple inducible gene regulation system | RHEOGENE, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002029075-A2 | MULTIPLE INDUCIBLE GENE REGULATION SYSTEM | ROHM AND HAAS COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
| US-6333318-B1 | USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187972-A1 | Methods for modulating expression of exogenous genes in mammalian systems | NR2E3, GFRA2, GFRA3 | GAA 3740/4885KMT2A 1788/4885HSD17B10 797/4885 |
| US-20260035432-A1 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | RORB, ICOS, RORC | GAA 2880/4885KMT2A 1078/4885HSD17B10 4055/4885 |
| US-20260098063-A1 | HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME | ANKRD54, POTEE, ANKK1 | GAA 4787/4885KMT2A 3819/4885HSD17B10 4846/4885 |
| US-20020110861-A1 | Multiple inducible gene regulation system | MYCBP, MYC, STAT3 | GAA 2541/4885KMT2A 1444/4885HSD17B10 1264/4885 |
| US-20250325665-A1 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | MUC1, CD40, TNFRSF1A | GAA 1000/4885KMT2A 3160/4885HSD17B10 4782/4885 |
| US-20020177564-A1 | METHOD FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO | OR51E2, HAVCR2, NGFR | GAA 2851/4885KMT2A 2440/4885HSD17B10 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.